BIOlogics in Severe Nasal POlyposis SurvEy
Key facts
- Who runs it
- University Hospital, Lille
- Where
- France1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 100 people, planned
- Started
- 10 Feb 2022
- Expected to end
- Jul 2027
- Type of study
- Observational
- Treatments tested
- Biologic treatments available in CRSwNP (dupilumab, mepolizumab and benralizumab according to their marketing approval)
- Record updated
- 29 April 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (7)Hide the full registry criteria
Who can take part
- Patients of over 18-year old requiring a biologic treatment for CRswNP in accordance with its marketing approval
Who cannot take part
- Oral corticotherapy in the previous month
- Biologic treatment with anti-IgE (omalizumab), anti-IL-5/IL-5R (mepolizumab, benralizumab) or anti-IL-4/IL-13R (dupilumab) or any other biotherapy for inflammatory diseases in the previous 6 months apart from ongoing biotherapies for severe asthma
- Hypersensitivity to humanized antibodies
- Documented SARS-Cov2 infection in the last 3 months with persistent olfactory disorders related to COVID
- Pregnant or breast-feeding women
- Patient without social coverage
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
With a prevalence of 2-4% in western countries, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is of major concern regarding its substantial impact on the social and physical quality of life. So far, endoscopic sinus surgery remains the treatment of choice when the first line of medical treatment with corticosteroid has failed.
Read full original descriptionShow less
During the last 15 years, several studies have shown that CRSwNP is associated with a T helper 2 (T2) immune response leading to B cell release of IgE, mucosal recruitment of eosinophils from bone marrow via Interleukin (IL)-5, IL-4 and IL-13 mediated chemoattractant production.
New biologic agents capable of blocking T2 cytokines have been developed in the field of eosinophil-associated diseases, shifting the paradigm of treatment for patients with CRSwNP. In the near future, endotype profiling with accurate biomarkers will be mandatory to tailor the treatment of nasal polyposis with specific biologic therapies.
Herein the investigators propose a prospective study monitoring medical records of CRSwNP patients who undergo biologic treatments. The objectives are to assess treatment efficacy on quality of life, to report clinical and biological criteria for prescription and to measure tolerance and compliance.
Treatments tested
- Biologic treatments available in CRSwNP (dupilumab, mepolizumab and benralizumab according to their marketing approval)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Real Life Assessment of Biologics Efficacy in Severe Chronic Rhinosinusitis With Nasal Polyps
- Publications
- Record updated
- 29 April 2026